Ab4AD (Antibodies for Alzheimer’s Disease) is a research initiative from Dr. Daniel Z. Bar (Tel Aviv University) that investigates the pathogen hypothesis of Alzheimer’s: common infections (notably herpes and P. gingivalis) appear to modulate AD risk. The team will analyze blood and saliva from dementia-free elderly individuals and compare them to AD patients and younger controls to identify protective antibodies. Instead of only targeting protein aggregation, Ab4AD focuses on why some exposed individuals stay dementia-free, using their natural antibody profiles as blueprints for protection. Funded and tracked through Molecule Catalyst, enabling visible milestones and community governance via IP Tokens (IPTs).
What is the highest value AB4AD (Antibodies for Alzheimer's Disease) (AB4AD) has ever reached?
AB4AD (Antibodies for Alzheimer's Disease) (AB4AD) reached its peak price at 0.3751 $ on 15 September 2025, approximately 15 hours ago ago. Presently, the current price is -0.1% lower than this all-time high.